Israeli Stocks: Bank Hapoalim, Teva, Hot, Discount Bank

Israel’s TA-25 Index gained 1 percent to 1,132.51 at the 4:30 p.m. close in Tel Aviv, trimming the monthly decline to 7.5 percent, the worst since November 2008. Investors traded about 1.1 billion shekels ($309 million) of shares and convertible securities today, according to Tel Aviv Stock Exchange data.

The following stocks rose or fell today. Symbols are in parentheses.

Biondvax Pharmaceuticals Ltd. (BNDX) The shares soared 13 percent to 1.82 shekels, bringing the two-day gain to 28 percent, the biggest such increase since October. The maker of flu vaccines said Aug. 29 after local markets closed it received approval to conduct a clinical trial of its universal flu vaccine at hospitals in Jerusalem and Tel Aviv.

Brainsway Ltd. (BRIN) surged the most since June 19, jumping 6.9 percent to 20.86 shekels. The maker of devices to treat neurological disorders reported test results, which showed its product managed to temporarily open the blood-brain barrier in seven of nine patients.

Israel Discount Bank Ltd. (DSCT) rose to the highest level since Aug. 3, advancing 3.1 percent to 6.14 shekels. The country’s third-largest bank said second-quarter profit increased to 231 million shekels from 156 million shekels a year earlier.

Bank Hapoalim Ltd. (POLI IT) gained 2.2 percent to 14.80 shekels, the highest close since Aug. 8. The country’s second- biggest bank by assets said second-quarter net income climbed 43 percent to 712 million shekels.

Hot Telecommunication System Ltd. (HOT) rose the most since Aug. 14, gaining 5.1 percent to 49.93 shekels. The provider of cable television and high-speed internet access reported a profit in the second quarter of 78 million shekels after a loss of 49 million shekels the year earlier. Separately, Barclays Capital raised the shares to “overweight” from “equal weight.”

Teva Pharmaceutical Industries Ltd. (TEVA) rose to the highest since Aug. 4, increasing 1.5 percent to 146 shekels. The world’s largest generic-drugmaker signed a license agreement with Sinclair IS Pharma Plc for rights to its oncology supportive care product.

To contact the reporter on this story: {Sharon Wrobel} in Tel Aviv at swrobel4@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.